Lymphoma Medical Services in China

Lymphoma is a heterogeneous group of malignant neoplasms originating from lymphoid tissue—primarily B cells, but also T cells and natural killer (NK) cells—within the immune system. It is broadly classified into two major categories: Hodgkin lymphoma (HL), characterized by the presence of Reed-Sternberg cells, and non-Hodgkin lymphoma (NHL), which encompasses over 90 distinct subtypes (e.g., diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma) with varying biological behaviors, clinical courses, and therapeutic responses. Pathogenesis involves cumulative genetic alterations—including chromosomal translocations (e.g., BCL2 in follicular lymphoma), somatic hypermutation errors, epigenetic dysregulation, and chronic antigenic stimulation—that disrupt normal lymphocyte proliferation, differentiation, and apoptosis. Immune dysfunction (e.g., HIV infection, post-transplant immunosuppression) and persistent viral infections (EBV, HTLV-1, HCV) further contribute to malignant transformation. Epidemiologically, lymphoma is the seventh most common cancer globally and the most frequent hematologic malignancy. In China, age-standardized incidence rates are approximately 5.2 per 100,000 for NHL and 0.7 per 100,000 for HL, with NHL incidence rising steadily—particularly among adults aged 60–75 years. Key risk factors include advanced age, male sex, autoimmune disorders (e.g., Sjögren’s syndrome, rheumatoid arthritis), immunosuppressive therapy, certain occupational exposures (e.g., pesticides, benzene), and familial predisposition. Lymphoma profoundly impacts quality of life: patients commonly experience debilitating fatigue, night sweats, unexplained weight loss, pruritus, and recurrent infections; psychological burden—including anxiety, depression, and treatment-related uncertainty—is prevalent; and long-term survivors may face late effects such as secondary cancers, cardiovascular toxicity, infertility, and neurocognitive deficits. Treatment-related side effects (e.g., chemotherapy-induced neuropathy, immunotherapy-related cytokine release syndrome) further compromise functional status and daily living activities. Early diagnosis remains challenging due to nonspecific symptoms mimicking benign conditions (e.g., mononucleosis, chronic fatigue syndrome), underscoring the need for heightened clinical suspicion and timely referral to hematology specialists for comprehensive evaluation—including biopsy, flow cytometry, molecular profiling, and PET-CT staging.

Lymphoma is a heterogeneous group of hematologic malignancies arising from lymphoid progenitor cells—primarily B lymphocytes (accounting for ~90% of cases), less commonly T lymphocytes or natural killer (NK) cells. Unlike solid tumors, lymphomas lack a single unifying etiology; rather, they result from the accumulation of genetic, epigenetic, immunologic, and environmental insults that disrupt normal lymphocyte development, activation, proliferation, and apoptosis. The fundamental pathogenic mechanism involves malignant transformation of clonal lymphoid cells, often driven by recurrent chromosomal translocations (e.g., t(14;18) in follicular lymphoma leading to BCL2 overexpression; t(8;14) in Burkitt lymphoma causing MYC dysregulation), somatic hypermutation errors, and aberrant class-switch recombination. These molecular lesions confer survival advantages, evade immune surveillance, and promote unchecked proliferation.

Immunosuppression represents a major trigger and risk factor. Chronic antigenic stimulation—whether from persistent infections or autoimmune dysregulation—sustains lymphocyte activation and increases the likelihood of oncogenic mutations. Notably, Epstein-Barr virus (EBV) is causally implicated in endemic Burkitt lymphoma, post-transplant lymphoproliferative disorder (PTLD), lymphomatoid granulomatosis, and subsets of diffuse large B-cell lymphoma (DLBCL), particularly in immunocompromised hosts. Helicobacter pylori infection is strongly associated with gastric mucosa-associated lymphoid tissue (MALT) lymphoma, where eradication therapy can induce complete remission in early-stage disease. Human T-lymphotropic virus type 1 (HTLV-1) is etiologically linked to adult T-cell leukemia/lymphoma (ATLL), while hepatitis C virus (HCV) shows epidemiologic associations with marginal zone lymphoma and splenic lymphoma with villous lymphocytes.

Genetic predisposition contributes significantly. First-degree relatives of lymphoma patients exhibit a 2–3-fold increased risk, suggesting heritable susceptibility. Germline variants in immune-regulatory genes—including TNF, IL10, and HLA class II alleles—modulate lymphoma risk. Inherited syndromes such as ataxia-telangiectasia (ATM mutations), Nijmegen breakage syndrome (NBN), and severe combined immunodeficiency (SCID) confer markedly elevated lymphoma incidence due to defective DNA repair and impaired lymphoid maturation. Polymorphisms in genes involved in xenobiotic metabolism (e.g., GSTM1 null genotype) and folate pathway enzymes (e.g., MTHFR) may further modulate individual susceptibility.

Environmental exposures are well-documented contributors. Prolonged occupational exposure to benzene, certain pesticides (e.g., organochlorines), herbicides (e.g., phenoxyacetic acids), and solvents increases risk—likely via induction of oxidative stress, DNA adduct formation, and disruption of hematopoietic stem cell homeostasis. Ionizing radiation, including therapeutic radiation for prior malignancies or historical diagnostic exposures, elevates risk for both Hodgkin and non-Hodgkin lymphoma (NHL). Smoking is associated with modestly increased risk for several NHL subtypes, particularly follicular lymphoma, possibly through chronic inflammation and immunomodulation. Obesity (BMI ≥30 kg/m²) is an independent risk factor for DLBCL and follicular lymphoma, potentially mediated by adipokine-driven chronic inflammation, insulin resistance, and altered cytokine profiles (e.g., elevated leptin, reduced adiponectin).

Demographic and clinical factors also influence risk. Age is a strong determinant: incidence rises steadily after age 60 for most B-cell lymphomas, whereas HL peaks in young adulthood and again after age 65. Male sex confers a ~1.5-fold higher risk for most NHL subtypes. Autoimmune conditions—including rheumatoid arthritis, Sjögren syndrome, systemic lupus erythematosus, and celiac disease—are associated with 2–8-fold increased NHL risk, likely reflecting chronic B-cell activation and inflammatory microenvironment remodeling. Iatrogenic immunosuppression—particularly calcineurin inhibitors (cyclosporine, tacrolimus) and anti-CD20 monoclonal antibodies used in transplantation or autoimmune disease—substantially elevates PTLD risk. Finally, socioeconomic factors may indirectly contribute via disparities in infection exposure (e.g., EBV serostatus), healthcare access, and environmental toxin burden. While no single cause suffices to explain lymphomagenesis, the convergence of genetic vulnerability, immune dysregulation, persistent antigenic drive, and environmental carcinogen exposure creates the permissive milieu for malignant lymphoid expansion.

Lymphoma, a heterogeneous group of hematologic malignancies arising from lymphoid cells—primarily B lymphocytes (90–95% of cases), less commonly T or natural killer (NK) cells—is broadly classified into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Clinical presentation varies significantly by subtype, disease stage, tumor burden, and host immune status. Early symptoms are often nonspecific and insidious, leading to delayed diagnosis; thus, heightened clinical suspicion is essential in patients with persistent, unexplained systemic complaints.

Early symptoms frequently include painless, progressive lymphadenopathy—most commonly involving cervical, supraclavicular, axillary, or inguinal nodes. Supraclavicular node enlargement warrants particular concern due to its association with underlying thoracic or abdominal malignancy. In HL, mediastinal involvement may manifest early as asymptomatic anterior mediastinal mass on chest radiography, though some patients report subtle dyspnea, cough, or positional discomfort. Constitutional 'B symptoms'—fever (>38°C without infection), drenching night sweats, and unintentional weight loss (>10% body weight over six months)—may appear early in aggressive subtypes (e.g., diffuse large B-cell lymphoma [DLBCL], lymphoblastic lymphoma) or advanced HL. Fatigue, low-grade malaise, and decreased exercise tolerance are common prodromal features, often attributed erroneously to stress or viral illness.

Typical symptoms reflect anatomical distribution and tumor biology. Peripheral lymphadenopathy remains the hallmark: nodes are typically rubbery, mobile, non-tender, and non-inflammatory. Extranodal involvement occurs in ~30–40% of NHL cases and defines primary extranodal lymphomas (e.g., gastric MALT lymphoma presenting with dyspepsia, GI bleeding, or iron-deficiency anemia; primary CNS lymphoma causing headache, focal neurologic deficits, or altered mental status; primary testicular lymphoma with painless testicular swelling). Mediastinal masses may cause superior vena cava syndrome (facial plethora, arm edema, distended neck veins), while bulky retroperitoneal disease can lead to back pain or hydronephrosis. Gastrointestinal lymphomas may present with obstruction, perforation, or protein-losing enteropathy. Cutaneous lymphomas (e.g., mycosis fungoides) classically begin with chronic, pruritic, scaly patches or plaques resistant to topical steroids.

Accompanying symptoms stem from immune dysregulation and cytokine release. Pruritus—often generalized and refractory—is highly characteristic of HL (up to 30% of cases) and correlates with adverse prognosis. Alcohol-induced lymph node pain, though rare (<10%), is pathognomonic for HL. Autoimmune phenomena occur in up to 25% of patients, including autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), or pure red cell aplasia—particularly associated with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and splenic marginal zone lymphoma. Paraneoplastic syndromes include dermatomyositis (especially with ovarian or gastric adenocarcinoma-associated lymphoma), neuropathies (e.g., anti-MAG neuropathy in IgM monoclonal gammopathy of undetermined significance [MGUS]-associated lymphoma), and hypercalcemia (via PTHrP secretion or osteolytic lesions in adult T-cell leukemia/lymphoma).

Complications arise from tumor infiltration, treatment toxicity, or immunosuppression. Bone marrow involvement leads to cytopenias—pancytopenia in advanced disease—and increases risk of infection and hemorrhage. Central nervous system (CNS) relapse or primary involvement carries high morbidity and mortality; DLBCL with MYC/BCL2 double-hit genetics has elevated CNS penetration risk. Lymphomatous meningitis presents with headache, cranial nerve palsies, and radicular pain. Tumor lysis syndrome (TLS) is an oncologic emergency in high-grade lymphomas (e.g., Burkitt lymphoma, lymphoblastic lymphoma) following initiation of chemotherapy, characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and acute kidney injury. Richter transformation—progression of CLL/SLL to aggressive DLBCL or Hodgkin-like lymphoma—confers rapid clinical deterioration, B symptoms, and markedly shortened survival. Infection-related complications are frequent due to inherent immune dysfunction (e.g., hypogammaglobulinemia in CLL) and therapy-induced neutropenia or T-cell depletion.

Diagnosis requires histopathologic confirmation via excisional lymph node biopsy—the gold standard—preferably of the largest, most accessible node. Core needle biopsy is insufficient for initial diagnosis due to sampling error and architectural distortion. Immunohistochemistry (IHC) panels assess lineage (CD20, CD3, CD30, CD15), proliferation index (Ki-67), and aberrant markers (e.g., BCL2, BCL6, MYC). Flow cytometry identifies clonality and surface immunophenotype. Molecular studies—including fluorescence in situ hybridization (FISH) for translocations (e.g., t(14;18) in follicular lymphoma, t(8;14) in Burkitt), PCR for immunoglobulin/T-cell receptor gene rearrangements, and next-generation sequencing (NGS) for somatic mutations (e.g., EZH2, CREBBP, TP53)—are integral to subclassification and prognostication. Staging follows the Lugano classification (modified Ann Arbor), incorporating CT, PET/CT (critical for metabolic assessment and response evaluation), bone marrow biopsy, and lumbar puncture when CNS involvement is suspected. Serum lactate dehydrogenase (LDH), β2-microglobulin, and albumin inform prognostic indices (e.g., International Prognostic Index [IPI] for NHL; IPS for HL).

Differential diagnosis must exclude reactive lymphadenopathies (e.g., infectious mononucleosis, toxoplasmosis, HIV-associated lymphadenopathy), autoimmune disorders (sarcoidosis, systemic lupus erythematosus), metastatic carcinoma (especially with isolated supraclavicular or Virchow node involvement), and other hematologic neoplasms (leukemias, myeloproliferative neoplasms, multiple myeloma). Key distinguishing features include absence of neutrophilia or CRP elevation in lymphoma versus acute infection; lack of granulomas or caseation in sarcoidosis/tuberculosis; and clonal immunoglobulin gene rearrangements absent in reactive conditions. Flow cytometry helps differentiate CLL/SLL from reactive lymphocytosis, while PET avidity and nodal architecture on biopsy clarify indeterminate cases. Importantly, persistent lymphadenopathy >4–6 weeks, especially with B symptoms or systemic signs, mandates tissue diagnosis—empirical antibiotic trials are inappropriate and delay definitive management.

Lymphoma is a heterogeneous group of hematologic malignancies originating from lymphoid tissue, broadly classified into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), with NHL accounting for approximately 90% of cases. Treatment strategies are highly individualized, guided by histopathologic subtype, disease stage, molecular and genetic profiling, patient age, performance status, and comorbidities. In the Department of Hematology, management integrates risk-adapted, evidence-based approaches grounded in international guidelines (e.g., NCCN, ESMO, Lugano Classification) while incorporating regionally validated protocols and innovations.

Conservative treatment—often termed 'active surveillance' or 'watch-and-wait'—is reserved exclusively for select indolent lymphomas demonstrating minimal tumor burden and no B symptoms (fever >38°C, drenching night sweats, weight loss >10% in 6 months), organ dysfunction, cytopenias, or rapidly progressive disease. This approach is most commonly applied to asymptomatic early-stage follicular lymphoma (FL), marginal zone lymphoma (MZL), or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). During surveillance, patients undergo clinical evaluation every 2–3 months, complete blood counts, lactate dehydrogenase (LDH), beta-2-microglobulin, and imaging (e.g., contrast-enhanced CT or PET/CT) every 6–12 months. The rationale is to defer cytotoxic therapy until clinically indicated, thereby avoiding unnecessary toxicity without compromising overall survival—a strategy supported by long-term data from the FOLL05 and PRIMA trials.

Pharmacotherapy constitutes the cornerstone of lymphoma management. For aggressive B-cell lymphomas—including diffuse large B-cell lymphoma (DLBCL)—first-line therapy remains R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), administered every 21 days for six cycles. Rituximab, a CD20-targeted monoclonal antibody, significantly improves progression-free and overall survival across multiple subtypes. In high-risk or relapsed/refractory DLBCL, intensified regimens (e.g., R-DHAP, R-ICE) followed by autologous stem cell transplantation (ASCT) are standard. Novel agents include polatuzumab vedotin (anti-CD79b antibody-drug conjugate), tafasitamab (Fc-enhanced anti-CD19), and bispecific T-cell engagers (e.g., glofitamab, epcoritamab). For mantle cell lymphoma (MCL), frontline options include bendamustine-rituximab (BR), R-CHOP, or cytarabine-containing regimens (e.g., R-DHAC), with ibrutinib or acalabrutinib (BTK inhibitors) used in relapse or as maintenance. Follicular lymphoma benefits from rituximab maintenance post-induction, and lenalidomide-rituximab (R²) has emerged as an effective chemo-free option. In HL, ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) remains first-line; for advanced or refractory disease, brentuximab vedotin (anti-CD30 ADC) and PD-1 inhibitors (nivolumab, pembrolizumab) have transformed outcomes. Supportive medications—including granulocyte colony-stimulating factor (G-CSF), antifungals, antivirals (e.g., acyclovir for herpes prophylaxis), and growth factor support—are routinely integrated to mitigate infection risk and hematologic toxicity.

Surgical intervention plays a very limited role in lymphoma management. Lymph node biopsy—typically excisional—is essential for definitive diagnosis and immunophenotyping but is diagnostic, not therapeutic. Rare exceptions include localized gastrointestinal MALT lymphoma with Helicobacter pylori–positive gastric involvement, where surgical resection may be considered if endoscopic eradication fails and there is evidence of transformation or perforation risk. Similarly, isolated cutaneous lymphomas unresponsive to radiotherapy or systemic therapy may undergo wide local excision. Surgery is contraindicated for staging or debulking in systemic disease, as it offers no survival benefit and risks complications including immunosuppression-related wound dehiscence and infection.

Treatment in China offers distinct advantages rooted in infrastructure, innovation, and integration. First, China’s national lymphoma registry and multi-center clinical trial networks (e.g., CHOP, C-LYMPH) enable rapid accrual for phase II/III trials evaluating novel agents—including domestically developed CAR-T therapies (e.g., relmacabtagene autoleucel for relapsed/refractory B-cell lymphoma, approved by NMPA in 2023). Second, cost-effective access to biosimilar rituximab and generic chemotherapy agents reduces financial toxicity, with many regimens covered under the National Reimbursement Drug List (NRDL). Third, integrative oncology programs—standardized across Tier-3 hospitals—combine evidence-based traditional Chinese medicine (TCM) adjuncts (e.g., Jianpi Jiedu decoction for chemotherapy-induced myelosuppression) with rigorous pharmacovigilance and outcome tracking. Fourth, centralized pathology review through the Chinese Lymphoma Working Group ensures diagnostic accuracy and molecular subtyping consistency, minimizing inter-institutional variability. Finally, digital health platforms facilitate remote monitoring, AI-assisted PET/CT interpretation, and real-time adverse event reporting—enhancing continuity of care across urban and rural settings.

Recovery and long-term follow-up require multidimensional support. Patients should undergo structured survivorship planning beginning at treatment completion: physical assessments (including cardiac echo for anthracycline-exposed patients), thyroid function tests (post-radiation), and screening for secondary malignancies (e.g., breast, lung, skin cancers). Vaccination status must be reviewed—non-live vaccines (e.g., influenza, pneumococcal conjugate, COVID-19 mRNA) should be administered ≥6 months post-chemotherapy or ASCT; live vaccines are contraindicated for ≥24 months. Lifestyle counseling emphasizes smoking cessation, moderate aerobic exercise (150 min/week), Mediterranean-style nutrition rich in antioxidants and fiber, and avoidance of immunosuppressive herbal supplements without hematologist approval. Psychosocial support—including cognitive behavioral therapy and peer-led lymphoma support groups—is strongly recommended, given elevated rates of anxiety, depression, and cancer-related fatigue. Regular surveillance includes CBC, LDH, and imaging every 3–6 months for first two years, then annually up to five years; PET/CT is reserved for suspected relapse. Patients receiving BTK inhibitors require ongoing cardiovascular monitoring (BP, ECG), while those on lenalidomide need monthly CBCs and venous thromboembolism prophylaxis. Finally, fertility preservation counseling should occur prior to alkylator-based regimens, especially in adolescents and young adults. With comprehensive, personalized, and longitudinally coordinated care, 5-year overall survival exceeds 90% for early-stage HL and 70–80% for localized DLBCL—underscoring the importance of timely referral to specialized hematology centers.